Why IMU is a multi multi bagger, page-22051

I like you am excited about current developments and aware of the opportunity of further fast track designations. I am simply suggesting we now focus further out toward a much broader expansion of the existing MAST Trial, and Vaxinia, than initially envisioned. It would be good to be in a position to amass a huge amount of data from a much larger pool than the gazetted 100 patients within the existing trial. Whether that is logistically performed through the current expansion, registration trials or Phase 2, planning for larger numbers through provision for future capital is a discussion that needs to happen now, if the results continue to be positive.

We all want to see this taken as far as it can, and with that in mind I'd be confident many of us would not want our status as a relatively small biotech with limited funding stand in the way of ground breaking, game changing and potentially paradigm shifting medicine.

WMHB